Showing results (271-280 of 435) with videos related to
Sort By:
Pageof 44
Med (New York, N.Y.)|May 19, 2022
Liquid biopsies for residual disease and recurrenceJonathan Chee Ming Wan, Tariq Imdadali Mughal, Pedram Razavi, et al.JCO Clinical Cancer Informatics|May 17, 2024
Automated, High-Throughput Platform to Generate a High-Reliability, Comprehensive Rectal Cancer DatabaseNeal Bhutiani, Mahmoud M G Yousef, Abdelrahman Yousef, et al.Scientific Reports|January 25, 2022
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterationsSeyed Pairawan, Argun Akcakanat, Scott Kopetz, et al.The Journal of Pathology|October 15, 2016
MIIP haploinsufficiency induces chromosomal instability and promotes tumour progression in colorectal cancerYan Sun, Ping Ji, Tao Chen, et al.Biorxiv : the Preprint Server for Biology|October 24, 2023
DeMixSC: a deconvolution framework that uses single-cell sequencing plus a small benchmark dataset for improved analysis of cell-type ratios in complex tissue samplesShuai Guo, Xiaoqian Liu, Xuesen Cheng, et al.Gut|June 14, 2017
The somatic mutation landscape of premalignant colorectal adenomaShu-Hong Lin, Gottumukkala S Raju, Chad Huff, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2015
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal CancerScott Kopetz, Jayesh Desai, Emily Chan, et al.Oncotarget|July 16, 2016
MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenonKanwal Raghav, Van Morris, Chad Tang, et al.The Oncologist|October 6, 2022
Mutation-Agnostic Detection of Colorectal Cancer Using Liquid Biopsy-Based Methylation-Specific SignaturesMohamed A Gouda, Dzifa Y Duose, Morten Lapin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 22, 2020
Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 TrialJonathan M Loree, Anthony Dowers, Dongsheng Tu, et al.Pageof 44